|Articles|October 19, 2011

FDA Grants 510(k) Clearance for Introcan Safety 3

Expanding its offering of passive safety devices to protect both clinicians and patients from needlestick injuries (NSIs), B. Braun Medical Inc. (B. Braun) recently announced that the Food and Drug Administration (FDA) granted 510(k) clearance of the companys Introcan Safety® 3 Closed IV Catheter, the next generation of B. Brauns Introcan Safety® IV Catheter. B. Braun made the announcement during the Association for Vascular Access 2011 annual scientific meeting in San Jose, Calif. in early October.

"Recent research confirms passive safety engineered devices are most effective for needlestick injury prevention," says Tom Sutton, vice president of vascular ccess and IV systems for B. Braun Medical Inc. "The Introcan Safety® 3 is designed to provide clinicians with not only an effective passive needlestick safety device, but also an added layer of safety and control with a bidirectional blood control valve to aid in the prevention of blood exposure each time the device is accessed."

The Introcan Safety® 3 features all elements of B. Brauns existing and proven Introcan Safety® IV Catheter. From insertion to advancing the catheter to needle removal, the Introcan Safety® 3 is designed to help protect clinicians and patients from NSIs as the device cannot be bypassed or activated inadvertently.

B. Brauns Introcan Safety® 3 will provide protection through Passive Safety Needle Shield to aid in the prevention of NSIs; Multiple Access Blood Control Valve to aid in the prevention of blood exposure; and Integrated Stabilization Platform to improve catheter stability and minimize movement within the vessel

For more information, visit www.introcansafety.bbraunusa.com or call (800) 227-2862.

Newsletter

Stay prepared and protected with the Infection Control Today newsletter, delivering essential updates, best practices, and expert insights for infection prevention professionals.

Subscribe

Related to this article

Water  (Adobe Stock 456102510 by stockphoto-graf)
Understanding current water quality is a starting point for ST108 implementation. John Kimsey, vice president of processing optimization and customer success for STERIS, spoke about his HSPA presentation on assessing readiness, distinguishing system qualification from routine testing, and understanding where water samples should be collected.
Image of Pathogens flying   (Adobe Stock weerasak)
Behind every landmark in infection prevention, from antimicrobial stewardship guidelines to the COVID-19 town halls that reached flight attendants and teachers, is a generation of physician-scientists who led SHEA through crises, organizational change, and scientific breakthroughs. Infection Control Today traces 30 years of SHEA presidents and the lasting mark they left on the field.
AORN26 New Orleans 2026  (Adobe Stock)
Missing instruments and processing delays can strain OR–SPD relationships. At AORN 2026, John Kimsey, vice president of processing optimization and customer success for STERIS, discusses understanding root causes, exploring off-site reprocessing for ambulatory surgical centers, and using hands-on simulation to help surgical teams see sterile processing from a different perspective.